Jarrell Hill, NP
Primary Care · Philadelphia, PANPI 1629663836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 297 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,038 and has fallen 76.8% since, to $474 in 2025. Among primary care clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$980
- AbbVie$736
- GSK$724
- Bayer$584
- Exact Sciences$326
- Boehringer Ingelheim$318
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,98698%
- Education$1022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $980 |
| AbbVie | 48 | $736 |
| GSK | 43 | $724 |
| Bayer | 24 | $584 |
| Exact Sciences | 14 | $326 |
| Boehringer Ingelheim | 16 | $318 |
| Sumitomo Pharma America, Inc. | 15 | $308 |
| Lilly USA, LLC | 14 | $247 |
| Astellas Pharma US Inc | 14 | $224 |
| Johnson & Johnson | 11 | $199 |
| UCB, Inc. | 5 | $132 |
| Gilead | 7 | $126 |
| Novo Nordisk | 8 | $123 |
| Teva Pharmaceuticals USA, Inc. | 6 | $104 |
| Sunovion Pharmaceuticals Inc. | 4 | $98 |
| Novartis | 5 | $96 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| Merck | 5 | $82 |
| Pfizer | 4 | $74 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Noven Therapeutics, LLC | 2 | $47 |
| Braeburn Inc. | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 1 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Protega Pharmaceutials Inc | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Corcept Therapeutics | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Bigfoot Biomedical Inc | 1 | $21 |
| SK Life Science, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,088 in reported general payments places this provider in the 90th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $81,270 |
| EliquisApixaban | 55 | $59,716 |
| JardianceEmpagliflozin | 44 | $53,214 |
| TrulicityDulaglutide | 55 | $52,400 |
| FarxigaDapagliflozin Propanediol | 47 | $49,253 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $47,011 |
| OzempicSemaglutide | 33 | $39,720 |
| EntrestoSacubitril/Valsartan | 39 | $35,772 |
| MyrbetriqMirabegron | 61 | $32,143 |
| XareltoRivaroxaban | 21 | $21,170 |
| LinzessLinaclotide | 30 | $19,577 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,657 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $14,833 |
| Famotidine | 138 | $11,581 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $10,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $724 | $96,955154 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $980 | $68,25588 claims |
| PfizerEliquis | $74 | $59,71655 claims |
| Boehringer IngelheimJardiance | $318 | $53,21444 claims |
| Lilly USA, LLCTrulicity | $247 | $52,40055 claims |
| GileadBiktarvy | $126 | $47,01112 claims |
| Novo NordiskOzempic | $123 | $39,72033 claims |
| NovartisEntresto | $96 | $35,77239 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $32,14361 claims |
| Johnson & JohnsonXarelto | $199 | $21,17021 claims |
| AbbVieLinzess | $736 | $19,57730 claims |
| MerckJanumet | $82 | $14,83327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Philadelphia
- Teresa GiamboyPhiladelphia$21K
- Galyna VorokhibPhiladelphia$12K
- Kaylee BakerPhiladelphia$7K
- Valerie DailyPhiladelphia$4K
- Adunni WardPhiladelphia$3K
- Avigad FeldmanPhiladelphia$3K
- Peggy DerussoPhiladelphia$3K
- Jennifer MalloyPhiladelphia$3K
- Emily MateyPhiladelphia$2K
- Kersten ReiderMount Penn$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.